Microcystic Lymphatic Malformation Clinical Trial
Official title:
A Multicenter, Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
The main purpose of this study is to assess the change in clinician global impression after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel compared to placebo in approximately 50 participants with microcystic lymphatic malformations.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050149 -
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
|
Phase 2 | |
Active, not recruiting |
NCT00975819 -
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
|
Phase 2 | |
Recruiting |
NCT06160739 -
Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations
|